Skip to main content

mogamulizumab

Generic: mogamulizumab·Brand: Poteligeo

mogamulizumab: 4 clinical trials tracked.

mogamulizumab evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about mogamulizumab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 2 study sponsors
Clinical Trials (4)

An Open-Label, Multicenter, Single Arm Study to Evaluate the Efficacy and Safety of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

NCT06285370·Phase 4·NYMXF

Primary endpoint: Overall Response Rate

Interventionalopen23 targetStarted 2023-05Completion 2025-118 sites · ChinaKyowa Kirin China Pharmaceutical Co., Ltd.

Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)

NCT05414500·Phase 1
Suspended

Primary endpoint: Rates of Adverse Events

Interventionalopen10 targetStarted 2023-05Completion 2027-071 site · United StatesUniversity of Alabama at Birmingham

A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL

NCT04930653·Phase 2
Suspended

Primary endpoint: Overall response rate (ORR)

Interventionalopen34 targetStarted 2022-10Completion 2028-063 sites · United StatesCity of Hope Medical Center

A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas

NCT04848064·Phase 1·FLNA
Recruiting

Primary endpoint: Incidence of adverse events

Interventionalopen12 targetStarted 2022-05Completion 2027-011 site · United StatesJohn Reneau